Article info

Concise report
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

Authors

  1. Correspondence to Dr Jeremy Sokolove, VA Palo Alto Health Care System, 3801 Miranda Avenue, Mail Stop 111G, Palo Alto, CA 94034, USA; sokolove{at}stanford.edu
View Full Text

Citation

Sokolove J, Schiff M, Fleischmann R, et al
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

Publication history

  • Received May 18, 2015
  • Revised July 28, 2015
  • Accepted August 19, 2015
  • First published September 10, 2015.
Online issue publication 
March 10, 2016

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.